Pharmaniaga Berhad (KLSE:PHARMA)
Malaysia · Delayed Price · Currency is MYR 0.2950
+0.0050 (1.72%)
At close: Feb 6, 2026
Pharmaniaga Berhad Income Statement
Financials in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 3,916 | 3,759 | 3,404 | 3,481 | 4,815 | 2,725 | |
Revenue Growth (YoY) | 8.09% | 10.43% | -2.20% | -27.71% | 76.69% | -3.38% |
Cost of Revenue | 3,498 | 3,219 | 3,097 | 3,138 | 4,185 | 2,430 |
Gross Profit | 418.31 | 540.49 | 307.82 | 342.72 | 630.02 | 295.2 |
Selling, General & Admin | 254.21 | 251.96 | 299.58 | 292.6 | 301.56 | 207.03 |
Amortization of Goodwill & Intangibles | 4.07 | 4.07 | 5.64 | 5.17 | 3.61 | 3.75 |
Operating Expenses | 281.82 | 279.57 | 328.27 | 314.72 | 322.64 | 227.61 |
Operating Income | 136.49 | 260.93 | -20.45 | 28 | 307.37 | 67.59 |
Interest Expense | -67.31 | -71.97 | -61.84 | -40.04 | -33.32 | -33.7 |
Interest & Investment Income | 3.85 | 2.25 | 1.48 | 0.91 | 1.52 | 0.63 |
Currency Exchange Gain (Loss) | - | - | 1.13 | 0.04 | 0.93 | 0.41 |
Other Non Operating Income (Expenses) | 3.5 | 2.89 | 0.66 | 3.03 | 0.51 | 0.87 |
EBT Excluding Unusual Items | 76.53 | 194.1 | -79.03 | -8.06 | 277 | 35.79 |
Impairment of Goodwill | - | - | - | -50.27 | - | - |
Gain (Loss) on Sale of Assets | 0.08 | 0.08 | 0.86 | 0.05 | 0.07 | - |
Asset Writedown | - | - | - | -552.31 | - | - |
Pretax Income | 76.61 | 194.18 | -78.16 | -610.59 | 277.08 | 35.79 |
Income Tax Expense | 32.21 | 60.39 | 0.58 | 17.07 | 104.87 | 9.52 |
Earnings From Continuing Operations | 44.4 | 133.79 | -78.74 | -627.65 | 172.21 | 26.27 |
Minority Interest in Earnings | -1.24 | -1.97 | -1.42 | -2.27 | -0.06 | 1.22 |
Net Income | 43.16 | 131.82 | -80.16 | -629.92 | 172.15 | 27.49 |
Net Income to Common | 43.16 | 131.82 | -80.16 | -629.92 | 172.15 | 27.49 |
Net Income Growth | -54.11% | - | - | - | 526.25% | - |
Shares Outstanding (Basic) | 2,327 | 1,441 | 1,368 | 1,310 | 1,309 | 1,307 |
Shares Outstanding (Diluted) | 2,327 | 1,441 | 1,368 | 1,310 | 1,309 | 1,309 |
Shares Change (YoY) | 61.41% | 5.38% | 4.40% | 0.05% | 0.04% | 0.33% |
EPS (Basic) | 0.02 | 0.09 | -0.06 | -0.48 | 0.13 | 0.02 |
EPS (Diluted) | 0.02 | 0.09 | -0.06 | -0.48 | 0.13 | 0.02 |
EPS Growth | -71.55% | - | - | - | 526.09% | - |
Free Cash Flow | -39.31 | 11.51 | -3.72 | -201.6 | -94.44 | -34.96 |
Free Cash Flow Per Share | -0.02 | 0.01 | -0.00 | -0.15 | -0.07 | -0.03 |
Dividend Per Share | - | - | - | 0.019 | 0.093 | 0.022 |
Dividend Growth | - | - | - | -79.57% | 322.73% | 29.41% |
Gross Margin | 10.68% | 14.38% | 9.04% | 9.85% | 13.08% | 10.83% |
Operating Margin | 3.48% | 6.94% | -0.60% | 0.80% | 6.38% | 2.48% |
Profit Margin | 1.10% | 3.51% | -2.35% | -18.10% | 3.57% | 1.01% |
Free Cash Flow Margin | -1.00% | 0.31% | -0.11% | -5.79% | -1.96% | -1.28% |
EBITDA | 158.68 | 288.49 | 7.35 | 55.62 | 335.28 | 94.43 |
EBITDA Margin | 4.05% | 7.67% | 0.22% | 1.60% | 6.96% | 3.46% |
D&A For EBITDA | 22.19 | 27.57 | 27.79 | 27.62 | 27.9 | 26.85 |
EBIT | 136.49 | 260.93 | -20.45 | 28 | 307.37 | 67.59 |
EBIT Margin | 3.48% | 6.94% | -0.60% | 0.80% | 6.38% | 2.48% |
Effective Tax Rate | 42.04% | 31.10% | - | - | 37.85% | 26.61% |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.